Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tomoxetine (Eli Lilly & Co).

Antonio Preti1

  • 1Genneruxi Medical Center, Cagliari, Italy. apreti@tin.it

Current Opinion in Investigational Drugs (London, England : 2000)
|May 22, 2002
PubMed
Summary
This summary is machine-generated.

Tomoxetine, a norepinephrine reuptake inhibitor, is being developed for attention deficit hyperactivity disorder (ADHD) and depression. Clinical trials and regulatory filings indicate a potential 2002 launch for this promising therapeutic agent.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Altered mirroring and self-face processing in schizophrenia: A systematic review.

Schizophrenia research·2026
Same author

Familial high-risk (FHR) for severe mental illness in clinical high-risk for psychosis (CHR-P): a systematic review and meta-analysis.

European archives of psychiatry and clinical neuroscience·2026
Same author

Rethinking the p-factor: A model of cumulative risk aggregation across development-Commentary on Caspi et al. (2026).

Journal of psychopathology and clinical science·2026
Same author

Antidepressants and Psychosis Risk: Disentangling Causal Effects From Prognostic Signals.

Acta psychiatrica Scandinavica·2026
Same author

Evening chronotype is associated with affective temperaments, emotional dysregulation, and bipolar-spectrum features: An observational study in 1997 adults from a large community sample.

Journal of affective disorders·2026
Same author

Spatial disruptions and the embodied Self in schizophrenia: toward a developmental framework.

Schizophrenia (Heidelberg, Germany)·2026
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Area of Science:

  • Pharmacology
  • Neuroscience
  • Psychiatry

Background:

  • Tomoxetine, a selective norepinephrine reuptake inhibitor, was initially explored by Eli Lilly in the 1980s for depression.
  • Development for depression was halted despite some efficacy, but research resumed in 1996 for ADHD.

Purpose of the Study:

  • To evaluate the efficacy and safety of tomoxetine for the treatment of attention deficit hyperactivity disorder (ADHD).
  • To assess the potential of tomoxetine as a therapeutic option for depressive disorders.

Main Methods:

  • Phase III clinical trials were conducted in the US.
  • Preclinical development and patent submissions were completed for ADHD indication.
  • Regulatory filings, including an NDA with the FDA, were submitted.

Related Experiment Videos

Main Results:

  • Tomoxetine demonstrated potential efficacy in phase II trials for depression.
  • Phase III trials for ADHD were underway as of May 2000.
  • Sales forecasts indicated significant market potential for tomoxetine.

Conclusions:

  • Tomoxetine shows promise as a treatment for both ADHD and depression.
  • Regulatory approval and market launch were anticipated for 2002.
  • The drug's development highlights a renewed focus on norepinephrine reuptake inhibition for psychiatric disorders.